GlassScriptPhysician profile
Alanna V Thomas
NPI 1386127868
$1,388.74
in general payments reported to CMS, 2019-2025
22 companies · $748 in 2025
The $748 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $397 · 2023: $148 · 2024: $95.69 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.41 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $210.01 | 2022-2023 | Kyprolis, Blincyto |
| Ucb, INC. | $204.83 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $180.82 | 2022-2025 | Tremfya |
| Genzyme Corporation | $170.37 | 2025 | |
| Abbvie INC. | $83.40 | 2024-2025 | |
| Celgene Corporation | $81.02 | 2022-2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $69.30 | 2023-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $50.35 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $45.27 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $41.35 | 2025 | |
| Gilead Sciences, INC. | $34.71 | 2022-2023 | Trodelvy |
| Karyopharm Therapeutics INC. | $31.69 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.77 | 2025 | Cabtreo |
| G1 Therapeutics, INC. | $24.12 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $21.33 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $20.23 | 2025 | |
| Biofrontera INC. | $19.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.10 | 2022 | |
| Genmab U.S., INC. | $18.88 | 2023 | Tivdak |
| Galderma Laboratories, L.P. | $17.43 | 2025 | Nemluvio |
| Seagen INC. | $13.89 | 2023 | Padcev |
| Organon LLC | $6.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alanna Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.